Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.495 USD | -1.27% | +1.45% | +110.24% |
May. 30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+110.24% | 341M | |
+18.32% | 125B | |
+14.00% | 109B | |
-2.86% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-11.79% | 16.64B | |
-0.15% | 13.45B | |
+22.39% | 11.32B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial